Usage of pioglitazone at Medanta, the Medicity.
Pioglitazone improves glycemic control by acting as an insulin sensitizer and is used in the management of Type 2 diabetes mellitus. Pioglitazone has recently been at the center of a controversy with regards to its safety. There is no clear consensus on how, when and in what dose the drug should be used in the management of diabetes. We have summarized our strategy on pioglitazone use in Type 2 diabetes in a large private tertiary care center - Medanta, the Medicity- which may help in generating further thought about positioning of this anti-diabetic molecule. We use pioglitazone as the fourth in the pecking order of oral anti-diabetic agents. We typically use pioglitazone in a dose of 15 mg/day. We avoid using pioglitazone with insulin. We do not use pioglitazone under following situations: In the presence of significant or proven cardiac disease, in patients who are struggling with their weight or need to lose weight, in patients at high risk for osteoporotic fractures, in patients with macular edema, in patients with pre-existing bladder cancer and would discontinue in case hematuria or any other symptom of bladder cancer develops. We continue to use the drug in patients well controlled on it without any evident side-effects or contraindications.
Department of Endocrinology, Medanta the Medicity, Gurgaon, Haryana, India.
Ambrish
A
Mithal
Department of Endocrinology, Medanta the Medicity, Gurgaon, Haryana, India.
Parjeet
P
Kaur
Department of Endocrinology, Medanta the Medicity, Gurgaon, Haryana, India.
Beena
B
Bansal
Department of Endocrinology, Medanta the Medicity, Gurgaon, Haryana, India.
Sunil Kumar
SK
Mishra
Department of Endocrinology, Medanta the Medicity, Gurgaon, Haryana, India.
Jasjeet S
JS
Wasir
Department of Endocrinology, Medanta the Medicity, Gurgaon, Haryana, India.
Ganesh
G
Jevalikar
Department of Endocrinology, Medanta the Medicity, Gurgaon, Haryana, India.
Shama
S
Mahendru
Pioglitazone; medanta; type 2 diabetes